

Out-of-pocket costs similar for infliximab, infliximab-dyyb

5 September 2018



modestly lower for infliximab-dyyb (\$2,185 versus \$2,667 and \$14,202 versus \$17,335, respectively). For infliximab-dyyb, plans universally required coinsurance cost-sharing; coinsurance rates were similar to infliximab (26.6 versus 28.4 percent of [drug](#) cost, respectively). Projected annual out-of-pocket costs were higher for infliximab-dyyb than for infliximab without gap discounts (\$5,118 versus \$3,432).

"Although biosimilar gap discounts begin in 2019, infliximab-dyyb may still not significantly reduce Part D beneficiaries' out-of-pocket [costs](#) given its high price and coinsurance cost-sharing similar to infliximab," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

(HealthDay)—Under Medicare Part D, out-of-pocket costs are similar for infliximab and its biosimilar infliximab-dyyb, according to a research letter published in the Sept. 4 issue of the *Journal of the American Medical Association*.

Copyright © 2018 [HealthDay](#). All rights reserved.

Jinoos Yazdany, M.D., M.P.H., from the University of California in San Francisco, and colleagues calculated the mean total cost and out-of-pocket cost requirements for infliximab-dyyb and infliximab assuming a standard eight-week dosing regimen. These national means were used to project maximum annual out-of-pocket costs if beneficiaries used each drug and no other prescriptions under a standard 2017 Part D benefit. As part of Part D, beneficiaries receive a [discount](#) during the coverage gap for brand-name drugs and biologics but not for biosimilars.

The researchers found that fewer plans covered infliximab-dyyb than infliximab (10 versus 96 percent of the 2,547 plans). The mean total cost per eight-week prescription and annually was

APA citation: Out-of-pocket costs similar for infliximab, infliximab-dyyb (2018, September 5) retrieved 15 November 2022 from <https://medicalxpress.com/news/2018-09-out-of-pocket-similar-infliximab-infliximab-dyyb.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.